RCS - N4 Pharma PLC - N4 Pharma Webinar on SRI Collaboration

N4 PharmaAnnouncement

26/04/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240426:nRSZ1231Ma&default-theme=true

RNS Number : 1231M  N4 Pharma PLC  26 April 2024

 

N4 Pharma plc

 ("N4 Pharma" or the "Company")

 

N4 Pharma Webinar on SRI Collaboration

 

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing
Nuvec®, a novel delivery system for cancer treatments and vaccines, will
provide a pre-recorded webinar relating to the Company's recent Collaboration
Agreement with SRI International Inc. which was announced on 25 April 2024.

 

The webinar will be available for viewing on 7 May 2024 at 10:00 BST, via the
Company's Investor Hub: investors.n4pharma.com/welcome
(http://investors.n4pharma.com/welcome) .

 

Investors will be notified via email of the presentation if they have signed
up to the N4 Pharma Investor Hub in advance, which can be done here:
investors.n4pharma.com/auth/signup (http://investors.n4pharma.com/auth/signup)
.

 

Investors are invited to submit questions in advance via N4 Pharma's Investor
Hub, and CEO Nigel Theobald will address as many as possible. Register and
submit questions at: investors.n4pharma.com (http://investors.n4pharma.com)

 

 

 

For more information please contact:

 

 N4 Pharma plc                                                        investors.n4pharma.com (http://investors.n4pharma.com)

 Nigel Theobald, CEO

 Luke Cairns, Executive Director
 SP Angel Corporate Finance LLP                                       Tel: +44(0)20 3470 0470

 Nominated Adviser and Joint Broker

 Matthew Johnson/Caroline Rowe/Kasia Brzozowska (Corporate Finance)

 Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)
 InvestorHub                                                          Sign up at investors.n4pharma.com (http://investors.n4pharma.com)

 Engage with us directly at N4 Pharma Investor Hub

                                                                      https://investors.n4pharma.com/link/4PKgJP
                                                                      (https://investors.n4pharma.com/link/4PKgJP)

 

About N4 Pharma

N4 Pharma is a specialist pharmaceutical company developing a novel delivery
system for oncology, gene therapy and vaccines using its unique silica
nanoparticle delivery system called Nuvec®.

 

N4 Pharma's business model is to partner with companies developing novel
antigens in these fields to use Nuvec® as the delivery vehicle for these
antigens. As these products progress through pre‐clinical and clinical
programs, N4 Pharma will seek to receive upfront payments, milestone payments
and ultimately royalty payments once products reach the market.

 

For further information on the Company visit www.n4pharma.com
(http://www.n4pharma.com) or sign up at www.investors.n4pharma.com
(http://www.investors.n4pharma.com) .

 

 

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAUVAURSAUSUUR